Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.

BACKGROUND: This study evaluated the clinical interpretations of single photon emission computed tomography (SPECT) using a cerebral blood flow and a dopamine transporter tracer in patients with chronic mild traumatic brain injury (TBI). The goal was to determine how these two different scan might b...

Full description

Bibliographic Details
Main Authors: Andrew B Newberg, Mijail Serruya, Andrew Gepty, Charles Intenzo, Todd Lewis, Daniel Amen, David S Russell, Nancy Wintering
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3901727?pdf=render
id doaj-97b0f86ed6594eb8bb4edf36cd07f993
record_format Article
spelling doaj-97b0f86ed6594eb8bb4edf36cd07f9932020-11-24T21:50:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8700910.1371/journal.pone.0087009Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.Andrew B NewbergMijail SerruyaAndrew GeptyCharles IntenzoTodd LewisDaniel AmenDavid S RussellNancy WinteringBACKGROUND: This study evaluated the clinical interpretations of single photon emission computed tomography (SPECT) using a cerebral blood flow and a dopamine transporter tracer in patients with chronic mild traumatic brain injury (TBI). The goal was to determine how these two different scan might be used and compared to each other in this patient population. METHODS AND FINDINGS: Twenty-five patients with persistent symptoms after a mild TBI underwent SPECT with both (99m)Tc exametazime to measure cerebral blood flow (CBF) and (123)I ioflupane to measure dopamine transporter (DAT) binding. The scans were interpreted by two expert readers blinded to any case information and were assessed for abnormal findings in comparison to 10 controls for each type of scan. Qualitative CBF scores for each cortical and subcortical region along with DAT binding scores for the striatum were compared to each other across subjects and to controls. In addition, symptoms were compared to brain scan findings. TBI patients had an average of 6 brain regions with abnormal perfusion compared to controls who had an average of 2 abnormal regions (p<0.001). Patient with headaches had lower CBF in the right frontal lobe, and higher CBF in the left parietal lobe compared to patients without headaches. Lower CBF in the right temporal lobe correlated with poorer reported physical health. Higher DAT binding was associated with more depressive symptoms and overall poorer reported mental health. There was no clear association between CBF and DAT binding in these patients. CONCLUSIONS: Overall, both scans detected abnormalities in brain function, but appear to reflect different types of physiological processes associated with chronic mild TBI symptoms. Both types of scans might have distinct uses in the evaluation of chronic TBI patients depending on the clinical scenario.http://europepmc.org/articles/PMC3901727?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Andrew B Newberg
Mijail Serruya
Andrew Gepty
Charles Intenzo
Todd Lewis
Daniel Amen
David S Russell
Nancy Wintering
spellingShingle Andrew B Newberg
Mijail Serruya
Andrew Gepty
Charles Intenzo
Todd Lewis
Daniel Amen
David S Russell
Nancy Wintering
Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.
PLoS ONE
author_facet Andrew B Newberg
Mijail Serruya
Andrew Gepty
Charles Intenzo
Todd Lewis
Daniel Amen
David S Russell
Nancy Wintering
author_sort Andrew B Newberg
title Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.
title_short Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.
title_full Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.
title_fullStr Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.
title_full_unstemmed Clinical comparison of 99mTc exametazime and 123I Ioflupane SPECT in patients with chronic mild traumatic brain injury.
title_sort clinical comparison of 99mtc exametazime and 123i ioflupane spect in patients with chronic mild traumatic brain injury.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description BACKGROUND: This study evaluated the clinical interpretations of single photon emission computed tomography (SPECT) using a cerebral blood flow and a dopamine transporter tracer in patients with chronic mild traumatic brain injury (TBI). The goal was to determine how these two different scan might be used and compared to each other in this patient population. METHODS AND FINDINGS: Twenty-five patients with persistent symptoms after a mild TBI underwent SPECT with both (99m)Tc exametazime to measure cerebral blood flow (CBF) and (123)I ioflupane to measure dopamine transporter (DAT) binding. The scans were interpreted by two expert readers blinded to any case information and were assessed for abnormal findings in comparison to 10 controls for each type of scan. Qualitative CBF scores for each cortical and subcortical region along with DAT binding scores for the striatum were compared to each other across subjects and to controls. In addition, symptoms were compared to brain scan findings. TBI patients had an average of 6 brain regions with abnormal perfusion compared to controls who had an average of 2 abnormal regions (p<0.001). Patient with headaches had lower CBF in the right frontal lobe, and higher CBF in the left parietal lobe compared to patients without headaches. Lower CBF in the right temporal lobe correlated with poorer reported physical health. Higher DAT binding was associated with more depressive symptoms and overall poorer reported mental health. There was no clear association between CBF and DAT binding in these patients. CONCLUSIONS: Overall, both scans detected abnormalities in brain function, but appear to reflect different types of physiological processes associated with chronic mild TBI symptoms. Both types of scans might have distinct uses in the evaluation of chronic TBI patients depending on the clinical scenario.
url http://europepmc.org/articles/PMC3901727?pdf=render
work_keys_str_mv AT andrewbnewberg clinicalcomparisonof99mtcexametazimeand123iioflupanespectinpatientswithchronicmildtraumaticbraininjury
AT mijailserruya clinicalcomparisonof99mtcexametazimeand123iioflupanespectinpatientswithchronicmildtraumaticbraininjury
AT andrewgepty clinicalcomparisonof99mtcexametazimeand123iioflupanespectinpatientswithchronicmildtraumaticbraininjury
AT charlesintenzo clinicalcomparisonof99mtcexametazimeand123iioflupanespectinpatientswithchronicmildtraumaticbraininjury
AT toddlewis clinicalcomparisonof99mtcexametazimeand123iioflupanespectinpatientswithchronicmildtraumaticbraininjury
AT danielamen clinicalcomparisonof99mtcexametazimeand123iioflupanespectinpatientswithchronicmildtraumaticbraininjury
AT davidsrussell clinicalcomparisonof99mtcexametazimeand123iioflupanespectinpatientswithchronicmildtraumaticbraininjury
AT nancywintering clinicalcomparisonof99mtcexametazimeand123iioflupanespectinpatientswithchronicmildtraumaticbraininjury
_version_ 1725882053047615488